symbol,year,quarter,category,company_name,sector,success,error,time_seconds,prediction,confidence,direction_score,actual_return_30d_pct,correct,trade_long,summary,le_DirectionScore,le_LongEligible,le_HardPositivesCount,le_HardVetoCount,le_GuidanceRaised,le_DemandAcceleration,le_MarginExpansion,le_FCFImprovement,le_VisibilityImproving,le_GuidanceCut,le_DemandSoftness,le_MarginWeakness,le_CashBurn,le_VisibilityWorsening,le_PricedInRisk
CRM,2022,3,LOSER,Salesforce,Technology,True,,82.4126250743866,DOWN,0.4,4,0.14354532196048964,False,False,"**PART 1 - Analysis:**
Management tone: Moderately optimistic — management used confident language, raised/maintained guidance and highlighted product momentum (Sales/Service Cloud scale, Slack outperformance, RPO/CRPO growth), but also acknowledged deceleration versus the prior quarter and focused on integration/operational execution. Main upside drivers: EPS beat, raised/tightened revenue guidance for Q4 and higher RPO/CRPO (visibility into future revenue), Slack and Commerce/Marketing momentu",4,NO,3,2,YES,NO,NO,YES,YES,NO,YES,YES,NO,NO,High
HSIC,2020,1,GAINER,Henry Schein,Healthcare,True,,89.69545412063599,DOWN,0.5,5,-0.05553577785688853,True,False,"**PART 1 - Analysis:**
Management tone: Balanced — the call showed a modest upside in reported EPS but no clear-upgrade to forward guidance or emphatic optimism; language was neither bullish nor cautious. Key upside drivers: an EPS beat (~+$0.27) and solid reported revenue (~$3.34B) that validate near-term fundamentals. Key downside drivers: small market reaction (+2.3%), lack of any announced guidance raise (implying guidance likely in-line), and no evidence of accelerating demand or margin exp",5,NO,0,0,NO,UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,NO,UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,Medium
BAX,2022,4,LOSER,Baxter International,Healthcare,True,,76.82700896263123,DOWN,0.3,3,-0.018737672583826553,True,False,"**PART 1 - Analysis:**
Management tone: Moderately cautious — commentary and guidance repeatedly referenced ""headwinds"", supply constraints, higher interest expense and a conservative posture (workforce reductions, spin-off timing), and guidance was cut/a toned-down range. Upside drivers: reported revenue growth (helped materially by the Legacy Hillrom acquisition), pockets of strength in Advanced Surgery, Clinical Nutrition and BioPharma Solutions, and a quantified $50M supply-constraint drag t",3,NO,0,4,NO,NO,NO,NO,NO,YES,YES,YES,NO,YES,High
